Floatz logo

TACROLIMUS

Ketamine

Weill Medical College of Cornell UniversitySmall moleculePhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Ketamine cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Stanford University
Phase 4BBB
Vts-K
Theresa Jacob, PhD, MPH
Phase 4BB
LIDOCAINE
Tanta University
Phase 4BB
L-Bupivacaine
Tanta University
Phase 4BB
FENTANYL
Aretaieion University Hospital
Phase 4BB

View all 16 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →